Tumor dissemination

Aoki, K., Furuhata, S., Hatanaka, K., et al. (2001). Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Then, 8, 508-514. 

As shown representatively in Figure 12.2, annexin is differentially expressed in RCC lesions compared to normal kidney epithelium. This suggests a role for annexin IV in tumor dissemination (Zimmermann et al., 2004). 

Hagmar, B. and Ryd, W. (1977). Tumor cell locomotion A factor in metastasis formation Influence of cytochalasin B on a tumor dissemination pattern. Int. J. Cancer 19, 576-580. 

The initial observations relating CD44 expression to tumor dissemination were made in human non-Hodgkin s lymphomas by us and the group of Jalkanen (Pals et al., 1989 Horst et al., 1990 Koopman et al., 1993 Jalka-nen et al., 1990,1991). In these studies, expression of CD44 on human lym-... 

In larger lesions, the array is withdrawn and redeployed anteriorly at 1.5- to 2.0-cm intervals into the tumor. After the hooks are fully deployed, the electrode is connected to the RF generator. The heating protocol for all the available needles is provided by the manufacturer. In general, the generator is started at a lower power setting and is subsequently increased in 10-W increments at 1-min intervals. The endpoint of RF application is the appearance of a rapid increase in tissue impedance (Roll-off) around the electrode. When this occurs, the RF application is automatically terminated. This process is repeated starting at 70% of the roll-off power until a second increase of the impedance occurs. Since the time point of the rapid increase in tissue impedance cannot be predicted, the ablation time needed varies dramatically between different tumor sizes and nodules. At the end of the procedure the needle track is ablated to prevent any tumor dissemination. Therefore, the tip has to be unisolated prior to the insertion of the needle. 

Other potential modes for administering GdDTPA, high-dose intraventricular or intrathecal injection or both, may have a supplemental killing effect when there is subependymal or intraventricular tumor dissemination. 

Matei, D. Tissue transglutaminase modulators for treatment of peritoneal ovarian tumor dissemination. PCT Int. Appl. WO 2008098129, 2008 Chem. Abstr. 2008, 149, 259456. 

---